Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.

Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic kaposi sarcoma / F. Ingegnoli, A. Tourlaki, R. Gualtierotti. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - 34:2(2014 Feb), pp. 159-161. [10.1007/s40261-013-0159-9]

Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic kaposi sarcoma

F. Ingegnoli
Primo
;
A. Tourlaki
Secondo
;
R. Gualtierotti
Ultimo
2014

Abstract

Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.
rheumatoid arthritis ; rituximab ; kaposi sarcoma
Settore MED/16 - Reumatologia
Settore MED/35 - Malattie Cutanee e Veneree
feb-2014
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/231955
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact